![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Molecular Pharmacology Limited (PK) | USOTC:MLPH | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0007 | 0.0008 | 0.0007 | 0.00 | 15:05:08 |
OMB APPROVAL |
OMB Number: 3235-0058 |
Expires: August 31, 2015 |
Estimated average burden
hours per response. . .2.50 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
(Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ X ] Form 10-Q [ ] Form N-SAR
1
[ X ] |
(b) |
The subject annual report, semi-annual report, transition report on Form 10-K, Form 2-F, 11-F, or From N-SAR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and | ||
[ ] |
(c) |
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. | ||
PART III - NARRATIVE | ||||
State below in reasonable detail the reasons why form 10-K, 11-K, 20-F, 10-Q or N-SAR or portion thereof could not be filed within the prescribed time period. | ||||
There was a delay in the registrant's legal counsel reviewing the Form 10-Q making it impossible for the registrant to complete the filing before February 17, 2015. | ||||
PART IV- OTHER INFORMATION | ||||
(1) |
Name and telephone number of person to contact in regard to this notification. | |||
Jeffrey Edwards |
Chief Executive Officer |
011-61-8-9443-3011 |
||
(Name) |
(Title) |
(Telephone Number) |
||
(2) |
Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer if no, identify report(s). | |||
[ X ] Yes |
[ ] No |
|||
(3) |
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? | |||
[ ] Yes |
[ X ] No |
|||
If so, attach an explanation of the anticipated change, both narrative and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made - Corporate offices and management changes. | ||||
N/A |
||||
MOLECULAR PHARMACOLOGY (USA) LIMITED
|
||||
has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized. |
||||
|
||||
Date: February 17, 2015 | By: /s/ Jeffrey Edwards_____________ | |||
Name: Jeffrey Edwards | ||||
|
Title: Chief Executive Officer |
2
1 Year Molecular Pharmacology (PK) Chart |
1 Month Molecular Pharmacology (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions